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GM1 Ganglioside Modifies 
α-Synuclein Toxicity and 
is Neuroprotective in a Rat 
α-Synuclein Model of Parkinson’s 
Disease
Jay S. Schneider1, Radha Aras1, Courtney K. Williams1, James B. Koprich2, 
Jonathan M. Brotchie2 & Vikrant Singh1
While GM1 may interact with α-synuclein in vitro to inhibit aggregation, the ability of GM1 to protect 
against α-synuclein toxicity in vivo has not been investigated. We used targeted adeno-associated 
viral vector (AAV) overexpression of human mutant α-synuclein (A53T) in the rat substantia nigra (SN) 
to produce degeneration of SN dopamine neurons, loss of striatal dopamine levels, and behavioral 
impairment. Some animals received daily GM1 ganglioside administration for 6 weeks, beginning 
24 hours after AAV-A53T administration or delayed start GM1 administration for 5 weeks beginning 3 
weeks after AAV-A53T administration. Both types of GM1 administration protected against loss of SN 
dopamine neurons and striatal dopamine levels, reduced α-synuclein aggregation, and delayed start 
administration of GM1 reversed early appearing behavioral deficits. These results extend prior positive 
results in MPTP models, are consistent with the results of a small clinical study of GM1 in PD patients 
that showed slowing of symptom progression with chronic use, and argue for the continued refinement 
and development of GM1 as a potential disease modifying therapy for PD.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopamine (DA)-producing 
neurons in the substantia nigra pars compacta (SNc), decreased levels of DA primarily in the caudate nucleus and 
putamen, accumulation of insoluble α-synuclein aggregates (i.e., Lewy bodies and Lewy neurites)1, and a slowly 
progressive worsening of clinical symptoms. Current pharmacotherapies for PD improve many of the motor signs 
and symptoms of the disease but no drug has yet been identified that definitively slows or stops the progression of 
PD. Disease modifying therapies that can alter clinical progression are sorely needed, however, efforts at finding 
such therapies have been limited in part due to uncertainty regarding the pathogenic processes contributing to 
DA neuron degeneration in PD that should be targeted by a disease modifying therapy.
Research from our group2,3 and others4,5 suggests that one potential pathogenic mechanism contributing to 
PD may involve dysregulation of ganglioside synthesis and expression that may contribute to the vulnerability 
and degeneration of DA neurons in PD. Gangliosides are glycosphingolipids bearing a ceramide anchor, an oligo-
saccharide, and one or more sialic acid residues6. The major ganglioside species in brain are GM1, GD1a, GD1b, 
and GT1b7, all contributing to the lipid composition of plasma and intracellular membranes. GM1 and other 
gangliosides are components of membrane signaling domains called lipid rafts, and in this regard, GM1 contrib-
utes to regulating signal transduction for directing neuronal development and cell survival and for modulating 
a wide variety of cell functions8. Further, at least four proteins associated with PD (LRRK2, Parkin, PINK1, and 
α-synuclein), have been found to associate with lipid rafts and some colocalize with GM1 (along with other raft 
markers) suggesting that alterations of the GM1-raft association could influence cellular functions dependent 
on these proteins9,10. In addition to effects exerted at the plasma membrane, GM1 also acts intracellularly where 
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it influences Ca2+ homeostasis, mitochondrial function, and lysosomal integrity, among other processes critical 
for normal cell function and survival11–14. Preclinical studies have shown that treatment with GM1 can be neu-
rotrophic or neuroprotective following different types of lesions [ex.,15,16] resulting in significant biochemical 
and behavioral recovery. In particular, GM1 rescued damaged SNc DA neurons, increased striatal DA levels 
and enhanced DA synthetic capacity in residual DA neurons in neurotoxin (MPTP)-induced models of PD17–23. 
Clinical studies of GM1 in PD patients have also provided evidence for slowing of symptom progression with 
GM1 use24,25. Despite the positive preclinical and clinical findings related to GM1 and PD, the mechanisms 
through which GM1 exerts its potential neuroprotective effects are still uncertain.
Alpha-synuclein fibrillation and aggregation are considered to be important contributors to PD pathophysiol-
ogy26, with α-synuclein-containing cytoplasmic inclusions a histological hallmark of the disease27. Recent devel-
opment of animal models of PD that reproduce this aspect of the disease have been achieved using viral vector 
delivery of α-synuclein directly to SNc DA neurons. In particular, several studies have demonstrated PD-relevant 
and progressive neuropathological (including development of insoluble α-synuclein aggregates) and behavioral 
features in mice28, rats29,30, and non-human primates31 following SNc-targeted AAV-driven overexpression of 
human mutant A53T α-synuclein. Binding of α-synuclein to GM1, in vitro, inhibits fibril formation, dependent 
upon the amount of GM1 present8, with a similar effect of GM1 on A53T mutant α-synuclein8. Additionally, 
the interaction of GM1 and α-synuclein in vitro led to a complete resistance to fibrillar aggregation of acetylated 
α-synuclein, raising the possibility that binding to GM1-rich membranes could protect monomeric α-synuclein 
from pathogenic aggregation32. Using the AAV-A53T α-synuclein rat model, the present study was conducted to 
investigate the extent to which GM1 ganglioside administration could protect against α-synuclein toxicity and 
development of PD-relevant pathological changes and behavioral deficits.
Results
Early start GM1 administration partially protects motor behavior and striatal DA levels. The 
cylinder test was used to assess spontaneous forelimb use in AAV-A53T α-synuclein-transduced animals and there 
was a significant main effect of treatment, with a protective effect observed in GM1-treated animals (F(5,102) = 16.59, 
P < 0.0001). Animals that received AAV-A53T α-synuclein followed by saline for 6 weeks developed a significant 
asymmetry in paw use with preference for making contact with the cylinder with ipsilateral forepaw relative to 
the side of virus injection. At 3 weeks following AAV-A53T α-synuclein injection, saline-treated animals already 
showed a significant increase in percent ipsilateral limb use that continued to be observed at 6 weeks post virus 
injection (mean ± SEM: baseline: 48.1 ± 1.9%; 3 weeks: 74.2 ± 2.7%, 6 weeks: 72.9 ± 2.9%) (Fig. 1A). In animals 
that received GM1 administration beginning 24 hours after AAV-A53T α-synuclein injection, limb use asymme-
try (percent ipsilateral limb use) was also increased at 3 weeks and 6 weeks after AAV-A53T α-synuclein injection 
but this increase was only significantly different from baseline at 3 weeks (mean ± SEM: baseline: 50.1 ± 1.8%; 3 
weeks: 67.1 ± 3.7%, 6 weeks: 56.0 ± 2.5%) (Fig. 1A). The amount of limb use asymmetry was significantly less in 
GM1-treated animals at 6 weeks compared to saline-treated animals at 6 weeks (P < 0.0001) (Fig. 1A). Animals 
that received AAV empty vector injections had no significant changes in limb use (% ipsilateral limb use: baseline: 
48.8 ± 2.3%; 3 weeks: 53.7 ± 4.2%; 6 weeks: 58.5 ± 4.1%; (F(2,9) = 2.521, P = 0.1173).
Figure 1. Protective effect of early start GM1on spontaneous forelimb use and striatal dopamine levels. (A) 
At 3 weeks following AAV-A53T α-synuclein injection, saline-treated animals (N = 15) favored the use of the 
limb ipsilateral to the injection and this response continued to be observed at 6 weeks post virus injection. In 
animals that received GM1 administration beginning 24 hours after AAV-A53T α-synuclein injection (N = 21), 
use of the limb ipsilateral to the injection was also favored at 3 weeks post injection, but with continued GM1 
use, this response was reduced by 6 weeks post virus injection. ****P < 0.0001 vs. baseline (A53T/Saline Bx); 
***P = 0.0005; ^^^P = 0.0003 vs. baseline (A53T/GM1 Bx); ^^P = 0.0055 vs. 3 wk. (B) Striatal DA levels were 
significantly higher in GM1-treated animals vs. saline-treated animals (**P = 0.0072). (C) Striatal DOPAC/DA 
ratios were significantly higher in saline-treated animals vs. GM1-treated animals (**P = 0.0040).
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Six weeks following AAV-A53T α-synuclein injection, striatal DA levels on the side ipsilateral to the injection 
in saline-treated animals were 47.8 ± 4.5% of the DA levels on the side contralateral to the injection (i.e., the 
non-injected side). In animals that began receiving GM1 administration 24 hours after surgery, striatal DA levels 
on the side ipsilateral to the injection were 64.0 ± 3.5% of the DA levels on the side contralateral to the injection 
(t(34) = 2.858, P = 0.0072 vs. saline-treated) (Fig. 1B, Supplementary Table 1). DOPAC/DA ratios on the side ipsi-
lateral to the injection in the saline-treated animals were 154.5 ± 9.2% of the contralateral (non-injected) side 
while in GM1-treated animals, DOPAC/DA ratios on the side ipsilateral to the injection were 112.3 ± 9.5% of the 
contralateral (non-injected) side (t(34) = 3.092, P = 0.0040 vs. saline-treated) (Fig. 1C). Injection of the AAV empty 
vector had no significant effects on striatal DA levels (non-injected side: 10.57 ± 0.47 µg/g wet weight; injected 
side: 11.04 ± 0.69 µg/g wet weight, N = 9, P = 0.5775).
The positive effects observed with GM1 administration beginning 24 hours after AAV-A53T α-synuclein 
injection cannot be explained by GM1 interfering with the transduction of the A53T α-synuclein gene by the 
AAV vector and expression of α-synuclein protein. When assessed at 1 week following AAV-A53T α-synuclein 
injection, levels of striatal α-synuclein were no different in saline vs. GM1-treated animals, suggesting no influ-
ence of GM1 on A53T α-synuclein transduction or transport to the striatum (normalized OD: 0.014 ± 0.004 and 
0.017 ± 0.007, respectively, t(12) = 0.4412, P = 0.6669) (Fig. 2A,B). Immunohistochemical evaluation of the SNc 1 
week after AAV-A53T α-synuclein injection also showed no differences between saline and GM1-treated animals 
in α-synuclein accumulation in TH+ neurons (Fig. 2C,D).
Early start GM1 administration partially protects SN neurons against α-synuclein-induced tox-
icity. To investigate the potential protective role of GM1 in the context of PD-relevant pathology, we exam-
ined the extent to which GM1 administration affected survival of A53T α-synuclein–overexpressing nigral DA 
neurons. The number of TH+ cells in the SNc was significantly decreased on the side ipsilateral to the injection: 
AAV-A53T-α-synuclein injection resulted in a 60.0 ± 2.3% loss of TH+ neurons, compared to the contralateral 
(non-injected) side (Fig. 3A,B). Animals that received early start GM1 administration had 43.7 ± 2.7% loss of TH+ 
neurons, compared to the non-injected side (t(28) = 4.379, P = 0.0002) (Fig. 3A,B; Supplementary Table 2). Similarly, 
the number of cresyl violet-stained cells in the SNc was significantly influenced by AAV-A53T-α-synuclein injection 
and by GM1 treatment. AAV-A53T-α-synuclein injection caused a 54.9 ± 1.8% loss of cresyl violet-stained neurons, 
Figure 2. Early start GM1 administration did not affect α-synuclein expression or transport to the striatum. 
(A,B) When assessed 1 week following AAV-A53T α-synuclein injection, levels of striatal α-synuclein were 
no different in saline (N = 6) vs. GM1-treated animals (N = 6), suggesting no influence of GM1 on A53T α 
-synuclein transduction or transport to the striatum. Representative Wes Western blots are shown after cropping 
(full length images of blots are presented as Supplementary Fig. 2. (C) Double label immunofluorescence 1 week 
after AAV-A53T α -synuclein injection showed no differences between saline and GM1-treated animals in α 
-synuclein accumulation (green) in TH+ neurons (red) in the SNc.
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compared to the contralateral side. GM1-treated animals had only a 41.9 ± 2.5% loss of cresyl violet-stained neurons, 
compared to the contralateral side (t(28) = 3.997, P = 0.0004) (Supplementary Table 2). Injection of the AAV empty vec-
tor had no significant effects on SN neurons: counts of TH+ neurons were 95.4 ± 1.1% of the non-injected side; counts 
of cresyl violet-stained neurons were 95.6 ± 1.3% of the non-injected side.
Delayed start GM1 administration partially restores motor behavior and protects striatal 
DA levels. Animals that received AAV-A53T α-synuclein followed by saline for 8 weeks also developed a 
significant asymmetry in paw use with preference for making contact with the cylinder with the forepaw ipsi-
lateral to the virus injection (Fig. 4A). When tested at 3 weeks following AAV-A53T α-synuclein injection, 
saline-treated animals showed a significant increase in percent ipsilateral limb use, similar to what was seen in the 
animals described earlier, that continued to be observed at 8 weeks post virus injection (mean ± SEM; baseline: 
50.9 ± 2.4%; 3 weeks: 74.5 ± 3.8%, 8 weeks: 81.4 ± 4.5%) (Fig. 4A). There was a significant treatment effect favor-
ing the GM1-treated group (F(5,84) = 19.14, P < 0.0001). Animals assigned to the GM1 group had baseline percent 
ipsilateral limb use (50.0 ± 2.0%) comparable to that of the saline group and an increase in percent ipsilateral 
forelimb use at week 3 (74.9 ± 2.8%), also comparable to that observed in the saline group. These animals then 
received daily GM1 administration for the next five weeks and when tested again at week 8, showed a significant 
decrease in percent ipsilateral forelimb use (i.e, an increase in contralateral limb use) (61.5 ± 2.7%) compared to 
performance at week 3 just prior to receiving GM1 treatment (P = 0.0075 vs. week 3) (Fig. 4B).
Eight weeks following AAV-A53T α-synuclein injection, striatal DA levels on the virus injected side of the 
brain in saline-treated animals were 32.3 ± 5.0% of the DA levels on the contralateral (non-injected) side. In 
animals that began receiving GM1 administration 3 weeks after surgery, striatal DA levels on the virus ipsilateral 
(injected) side of the brain were 55.0 ± 3.9% of the DA levels on the contralateral side (t(29) = 3.565, P = 0.0013 
vs. saline-treated) (Fig. 4C). DOPAC levels on the injected side in the saline-treated animals were 69.4 ± 7.4% of 
the contralateral side while in GM1 treated animals, DOPAC levels on the injected side were 82.0 ± 8.4% of the 
non-injected side, an increase but not statistically significantly different from saline-treated animals. DOPAC/DA 
ratios on the side ipsilateral to the injection in the saline-treated animals were 181.1 ± 25.4% of the contralateral 
side while in GM1-treated animals, DOPAC/DA ratios on the side ipsilateral to the injection were 150.0 ± 10.9% 
of the contralateral side, although this difference was not statistically significant (Fig. 4D).
Delayed start GM1 administration partially protects SN neurons against α-synuclein-induced 
toxicity. We examined the extent to which delayed start administration of GM1 could affect survival of A53T 
α-synuclein–overexpressing nigral DA neurons. The number of TH+ cells in the SNc was significantly decreased 
Figure 3. Early start GM1 administration partially protected against loss of SNc dopaminergic neurons. (A) 
There was a significant protective effect of early start GM1 administration (N = 17) on the number of TH+ 
cells (***P = 0.0002) and the number of Nissl-stained cells (B) (***P = 0.0004 vs. saline-treated) in the SNc, 
compared to saline-treated animals (N = 13). (C) Immunhistochemical staining of TH+ cells in the SNc showed 
significant cell loss in a saline-treated animal and (D), a partial sparing of TH+ cells in a GM1-treated animal.
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on the side ipsilateral to the injection: AAV-A53T-α-synuclein injection resulted in a 63.3 ± 3.0% loss of TH+ 
neurons, compared to the contralateral (non-injected) side. Animals that received delayed start GM1 administra-
tion had 50.6 ± 2.1% loss of TH+ neurons, compared to the contralateral side (t(27) = 3.58, P = 0.0013) (Fig. 5A,B; 
Supplementary Table 2). The number of cresyl violet-stained cells in the SNc was also significantly influenced 
by AAV-A53T-α-synuclein injection and by delayed start GM1 treatment. AAV-A53T-α-synuclein injection 
caused a 58.2 ± 2.6% loss of cresyl violet-stained neurons, compared to the contralateral side. Delayed start 
GM1-treated animals had only a 45.5 ± 2.1% loss of cresyl violet-stained neurons, compared to the contralateral 
side (t(27) = 3.796, P = 0.0008) (Supplementary Table 2).
α-synuclein aggregation is reduced by GM1 administration. Since previous in vitro studies suggest 
that GM1 and α-synuclein (both wildtype and the A53T mutation) interact in a way that potentially inhibits 
pathogenic aggregation8, we hypothesized that GM1 administration to AAV-A53T overexpressing animals would 
result in less α-synuclein aggregation and thus smaller sized aggregates. Thus, we examined the effect of early or 
delayed start GM1 administration on the size of α-synuclein-positive swellings/aggregates in the striatum. The 
size distributions of striatal α-synuclein-positive aggregates in saline-treated compared to GM1-treated (start-
ing 24 hours after AAV-A53T administration) were significantly different (Kolmogorov-Smirnov D = 0.2945, 
P < 0.0001), with a clear shift to larger numbers of smaller sized aggregates and fewer larger sized aggregates in 
the GM1 group compared to the saline group (Fig. 6A,C). The maximum aggregate size measured in the saline 
group was 52.5 µm2 while the maximum aggregate size measured in the GM1-treated animals was 28.8 µm2.
Figure 4. Delayed start GM1 administration partially restores motor function and partially protects striatal 
dopamine levels. (A) At 3 weeks following AAV-A53T α-synuclein injection, saline-treated animals (N = 11) 
showed a significant preference for using the limb ipsilateral to the injection and that bias continued to be 
observed at 8 weeks post virus injection (****P < 0.0001 vs. baseline (Bx). (B) In the delayed start GM1 group 
(N = 17), animals also showed a significant preference for using the limb ipsilateral to the injection at 3 weeks 
post virus injection (****P < 0.0001 vs. Bx) but after 5 weeks of GM1 use (starting immediately after 3 week 
testing), limb use asymmetry was significantly reduced (**P = 0.0075 vs. 3 weeks). (C) Striatal DA levels were 
significantly higher in GM1-treated animals (N = 17) vs. saline-treated animals (N = 11) (**P = 0.0013 vs. 
saline-treated). (D) DOPAC/DA ratios were lower in the GM1-treated (N = 17) but not significantly reduced 
compared to saline-treated animals (N = 11).
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Similar results were obtained with measurements of aggregate size distributions in animals with delayed start 
GM1 administration compared to saline-treated animals. The size distributions of striatal α-synuclein-positive 
aggregates in saline-treated compared to GM1-treated (starting 3 weeks after AAV-A53T administration) were 
significantly different (Kolmogorov-Smirnov D = 0.154, P < 0.0001), with greater numbers of larger sized aggre-
gates in the saline group compared to the GM1 group (Fig. 6B,D). The maximum aggregate size measured in 
the saline group was 66.9 µm2 while the maximum aggregate size measured in the GM1-treated animals was 
29.3 µm2. Compared to animals that started receiving GM1 24 hours after AAV-A53T administration, animals 
that received GM1 starting 3 weeks after AAV-A53T administration had greater numbers of intermediate-sized 
aggregates (approximately 7–12 µm2), but like the early start GM1 group, had fewer larger sized aggregates than 
the saline group.
Although we did not quantify the accumulation of Ser129-phosphorylated α-synuclein, immunohistochemi-
cal visualization of Ser129-phosphorylated α-synuclein-positive neurons and neurites in the SN of GM1-treated 
and saline-treated animals showed less intense cytoplasmic Ser129-phosphorylated α-synuclein staining and fewer/
smaller nuclear aggregates in GM1-treated animals compared to saline-treated animals (Supplementary Fig. 1).
Discussion
GM1 ganglioside has had beneficial effects on striatal DA levels and behavior and has protected SNc DA neu-
rons against degeneration in neurotoxin (primarily MPTP) models of PD17–23. GM1 has also been shown to 
have symptomatic effects and with extended use, may slow symptom progression in PD patients24,33. The present 
study demonstrates that GM1 administration is also able to exert neuroprotective and potentially neurorestor-
ative effects on the nigrostriatal DA system in a PD model characterized by targeted overexpression of human 
mutated α-synuclein (A53T) in SNc neurons29. These data are particularly interesting considering that other 
compounds that have been found to be neuroprotective in MPTP mouse or nonhuman primate models of PD 
have not had this preclinical success translated to the α-synuclein model or to the clinic. Although there are 
several possible reasons why compounds such as GDNF, neurturin, CoQ10, CEP-1347, GPI-1485, pioglitazone, 
exenatide, and others that showed promising neuroprotective effects in MPTP models failed to demonstrate clear 
disease-modifying effects in clinical trials34, the relevance and translatability of the MPTP (and other toxin-based) 
models of PD have been called into question35, based on the assumption that the toxin models do not faithfully 
replicate key aspects of the disease35. However, clinical translational failures may be as much due to specific char-
acteristics of the compounds tested as to deficiencies in the preclinical models. Here we show that unlike these 
other compounds, GM1 is neuroprotective in mouse and nonhuman primate MPTP models17,18,21,23, is neuropro-
tective in an AAV-α-synuclein model that reproduces DA neuron degeneration and dysfunction based on a core 
Figure 5. Delayed start GM1 administration partially protected against loss of SNc dopaminergic neurons. 
(A) There was a significant protective effect of delayed start GM1 administration (N = 17) on the number of 
TH+ cells (**P = 0.0013) and the number of Nissl-stained cells (B) (***P = 0.0008 vs. saline-treated) in the 
SNc, compared to saline-treated animals (N = 12). (C) Immunohistochemical staining of TH+ cells in the SNc 
showed significant cell loss in a saline-treated animal and (D), a partial paring of TH+ cells in a GM1-treated 
animal.
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molecular feature of PD (i.e., toxicity associated with accumulation of aberrant α-synuclein29), and that these 
preclinical successes have translated to positive effects in initial clinical trials24,33.
In the current study, a behavioral deficit was observed on the cylinder test at 3 weeks following AAV-A53T 
α-synuclein injection. Although we did not euthanize animals in this study at this 3 week period, a previous 
in-depth characterization of this model, using exactly the same vector and vector concentration as used here, 
showed that the cylinder test deficit observed at 3 weeks appeared in the absence of significant loss of SN DA 
neurons or striatal DA levels but in the presence of moderate dystrophic axonal morphology in the striatum29. 
Animals treated with GM1 beginning 24 hours after AAV-A53T α-synuclein injection were already beginning to 
show reduced use of the forelimb contralateral to the injection when tested at 3 weeks and by 6 weeks following 
AAV-A53T α-synuclein injection, this effect became statistically significant, with the ratio of ipsilateral/contralat-
eral forelimb use approximating that observed at baseline (prior to AAV-A53T α-synuclein injection). At 6 weeks, 
GM1-treated animals also had significantly higher striatal DA levels than saline-treated animals. We also showed 
that early start GM1 treatment did not interfere with the expression or transport of α-synuclein. These results 
suggest that early start GM1 therapy, while not interfering with the transduction of A53T α-synuclein by the AAV 
vector and expression/transport of α-synuclein, did interfere with the pathological processes set in motion from 
the accumulation of α-synuclein.
Of considerable interest was the finding that delayed start GM1 treatment could significantly reverse the 
behavioral deficit observed at 3 weeks following AAV-A53T α-synuclein injection. As suggested by others29, the 
behavioral deficits seen at the 3 week time-point are a result of A53T α-synuclein-induced dysfunction of a rela-
tively anatomically intact nigrostriatal pathway. Starting GM1 therapy at this time-point was able to afford some 
protection against the degeneration of SNc DA neurons and loss of striatal DA even once the pathological process 
of α-synuclein accumulation had begun, and was able to reverse the forelimb use deficit observed at 3 weeks, as 
observed at 8 weeks post AAV-A53T α-synuclein injection.
The mechanisms underlying the neuroprotective efficacy of GM1 in this model are not entirely known at 
this time. We observed that in animals administered GM1 there was decreased aggregation of α-synuclein 
and we have preliminary observations that GM1 may also decrease α-synuclein phosphorylation, potentially 
decreasing the accumulation of toxic forms of α-synuclein. Phosphorylation of α-synuclein at Ser129 promotes 
α-synuclein fibril formation36 and the majority of α-synuclein deposited in Lewy bodies in the PD brain is 
Figure 6. GM1 treatment reduces the size of α-synuclein-positive aggregates in the striatum. (A) The size 
distributions of striatal α-synuclein-positive aggregates in saline-treated (N = 6) (red bars) compared to early 
start GM1-treated (blue bars) animals (N = 6) were significantly different (Kolmogorov-Smirnov D = 0.2945, 
P < 0.0001), with a clear shift to larger numbers of smaller sized aggregates and fewer larger sized aggregates in 
the early GM1 group compared to the saline-treated group. (B) The size distributions of striatal α-synuclein-
positive aggregates in the delayed GM1-treated group (N = 8) (blue bars) was also significantly different 
(Kolmogorov-Smirnov D = 0.154, P < 0.0001) than size distribution of aggregates in the saline-treated group 
(N = 7) (red bars), with greater numbers of larger sized aggregates in the saline-treated group compared to the 
GM1 group. (C) Photomicrographs of α-synuclein immunohistochemical staining in the striatum of saline-
treated (left) and early start GM1-treated (right) animals. Sizes of aggregates are notably smaller in the GM1-
treated animal. Arrow points to large α-synuclein-positive aggregate. (D) Photomicrographs of α-synuclein 
immunohistochemical staining in the striatum of saline-treated (left) and delayed start GM1-treated (right) 
animals. Sizes of aggregates are smaller in the delayed start GM1-treated animal, but the effect was not as 
dramatic as in the early-start GM1 animals. Arrow points to large α-synuclein-positive aggregate.
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extensively phosphorylated at Ser12936,37. A53T α-synuclein as well as wild type α-synuclein can form insoluble 
toxic fibrillar aggregates and mutant α-synuclein may be more prone to aggregation and toxicity than wild type 
α-synuclein38,39. We found that both early start and delayed start use of GM1 following AAV-A53T α-synuclein 
injection reduced the size of α-synuclein aggregates measured in the striatum. In vitro studies have shown a 
direct association between GM1 and α-synuclein, attributed to interaction between helical α-synuclein and both 
the sialic acid and carbohydrate moieties of GM1, and that this association with GM1 inhibited fibrillation8. As 
we and others have shown decreased expression of GM1 and other complex gangliosides in the SN in PD3,4 and 
decreased expression of genes involved in ganglioside biosynthesis in DAergic neurons in the PD SN2, it is con-
ceivable that reduced levels of gangliosides, and particularly GM1, in the PD SN may promote the accumulation 
of toxic α-synuclein and that administration of GM1 may provide sufficient amounts of this important sphingo-
lipid so as to at least partially inhibit the toxic aggregation of α-synuclein and provide some level of protection to 
SN DA neurons. This possibility is supported by studies with B4galnt1 knockout mice, devoid of GM1 and other 
a-series gangliosides, that reported increased amounts of α-synuclein aggregation in knockout mice devoid of 
GM1 that could at least be partially reduced by administration of GM1 and the semi-synthetic GM1 derivative 
LIGA-204.
Another possible mechanism underlying the neuroprotective effects of GM1 observed in the current study 
may involve influences of GM1 on autophagy and lysosomal function. Dysfunction of the autophagy-lysosomal 
pathway has been suggested to contribute to PD pathology40. Overexpression of A53T-α-synuclein suppresses 
autophagy and pathogenic A53T-α-synuclein is poorly processed and cleared by chaperone-mediated auto-
phagy41,42. Under conditions of impaired autophagy, GM1, either in vivo or in vitro, increased expression of 
autophagic markers and enhanced autophagy43. Depletion of endogenous gangliosides resulted in compromised 
lysosomal functions and suppression of autophagy, leading to accumulation of both α-synuclein and P123H 
β-synuclein in a cellular model of Lewy body disease14. It is possible that in the current study, autophagic pro-
cesses were impaired by A53T-α-synuclein overexpression contributing to enhanced α-synuclein aggregation 
and DAergic cell loss and that GM1 treatment enhanced lysosomal function and increased autophagic clearance 
of α-synuclein. Additional studies are now needed to investigate this potential mechanism in regard to the neu-
roprotective effects of GM1 in this model.
The AAV-A53T α-synuclein model that we used for this study was the same model described previously as 
producing a specific and progressive degeneration of the nigrostriatal DA system29. A limitation of our study is 
that animals were not euthanized at early time-points following AAV-A53T α-synuclein injection and thus, the 
progressive nature of the pathology, as previously described, was not verified. However, in early pilot studies when 
establishing the model, we were able to detect a steady increase in forelimb use asymmetry over the first 3 weeks 
post-injection. Although we performed a limited examination of phosphorylated Ser 129 α-synuclein expression 
by immunohistochemistry, there were not sufficient tissues available for systematic evaluation of levels of phos-
phorylated Ser 129 α-synuclein. Likewise, the presence of insoluble phosphorylated α-synuclein aggregates was 
not directly assessed. Striatal α-synuclein aggregates have been shown to be extensively phosphorylated at Ser129 
in rats with AAV-mediated A53T-α-synuclein overexpression44, however, in the current study, we only assessed 
total α-synuclein positive aggregates in the striatum and did not separately analyze Ser129-phosphorylated 
α-synuclein-positive aggregates. Follow-up studies are now needed to examine in more detail the relationship 
between GM1 administration and α-synuclein phosphorylation. Also, only one dose level of GM1 was used in 
this study and although the dose used was the same that has been shown to be neuroprotective in MPTP mouse 
models of PD, it is possible that the dose used may not have been optimal in the rat AAV-A53T α-synuclein 
model. Additionally, the effects of different durations of treatment with GM1 need to be investigated.
In conclusion, this study showed that GM1 ganglioside, previously shown to be neuroprotective in MPTP 
models of PD, also has neuroprotective effects in an AAV-A53T α-synuclein overexpression model of PD. 
Neuroprotective effects in this model, which is presumed to be more pathologically relevant to PD than neu-
rotoxin models, is in agreement with our clinical experience with GM1 in PD patients, where prolonged use of 
GM1 produced evidence of a potential disease modifying effect. Development of treatments that directly impact 
the underlying disease processes in PD and that can slow neuronal cell death and symptom progression remain 
an unmet need of the PD population45. Based on previous work and the current results, GM1 continues to have 
potential to be such a treatment, with the potential to protect DA neurons from dying as well as rescue and restore 
function to damaged but viable neurons, and thus continued clinical development of GM1 for PD is indicated.
Materials and Methods
Vector. The vector used in this study was the generous gift of Drs. J. Koprich and J. Brotchie, Toronto Western 
Research Institute. Full details of vector design can be found in Koprich et al.30. Briefly, a chimeric adeno-asso-
ciated vector (AAV) of a 1/2 serotype (capsid expresses AAV1 and AAV2 serotype proteins in a 1:1 ratio) with 
human A53T alpha synuclein expression driven by a chicken beta actin (CBA) promoter hybridized with the 
cytomegalovirus (CMV) immediate early enhancer sequence was used. A woodchuck post-transcriptional regu-
latory element (WPRE) and a bovine growth hormone polyadenylation sequence (bGH-polyA) were also incor-
porated to further enhance transcription following transduction. The vectors (AAV1/2-A53T and empty vector 
control) were produced by GeneDetect Ltd., Auckland, New Zealand. Viral titers were determined by quantitative 
PCR (Applied Biosystems 7900 QPCR) with primers directed to the WPRE region, thus representing the number 
of functional physical particles of AAV in the solution containing the genome to be delivered.
Animals and vector delivery. All animal procedures were approved by the Thomas Jefferson University 
Institutional Animal Care and Use Committee and conducted in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. Adult male Sprague-Dawley rats (Envigo), 250 to 
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300 g at the time of surgery, were housed three per cage with ad libitum access to food and water during a 12-hour 
light/dark cycle.
All surgeries were performed under general anesthesia using a mixture of ketamine (100 mg/kg, i.p.) and xyla-
zine (10 mg/kg, i.p.). Once animals were anesthetized, the head was shaved and surgically prepped with Betadine 
solution and alcohol before being placed in a Kopf stereotaxic frame with the incisor bar set at approximately 
3.5 mm below horizontal zero to achieve a flat skull position. The skin on the top of the skull was cut along the 
midline and retracted. Using coordinates AP: −5.3, L:2.2, D:7.5 below skull46, derived from bregma, a small 
burr hole was created over the SN on one side and a 36 gauge needle attached to a Hamilton syringe loaded with 
AAV-A53T-synuclein or empty vector control virus was slowly lowered into the brain and 2.0 µl was injected 
above the SN at a rate of 0.2 µl/min using a motorized syringe pump. Following a 5 minute wait period after com-
pletion of the injection, the needle was slowly withdrawn, the skin wound was closed, and post-surgery analgesia 
(meloxicam 1 mg/kg) was administered.
Some rats were randomly assigned to receive daily GM1 ganglioside (porcine brain derived GM1, 
30 mg/kg, i.p., Qilu Pharmaceutical Co., Ltd.) or similar volume saline injections beginning 24 hours after 
AAV-A53T-synuclein surgery and lasting for 6 weeks (early start group). Other animals were randomly assigned 
to receive daily GM1 ganglioside (porcine brain derived GM1, 30 mg/kg, i.p., Qilu Pharmaceutical Co.) or similar 
volume saline injections beginning 3 weeks after AAV-A53T-synuclein surgery and lasting for 5 weeks (delayed 
start group). The dose of 30 mg/kg was selected based on the following information: this dose of GM1 was previ-
ously found to be effective in MPTP lesion models in mice17,19; this dose was shown to be effective in stimulating 
regenerative responses in numerous rodent studies spanning a variety of central and peripheral lesion models47.
At the conclusion of the study, animals were euthanized, fresh brains were rapidly removed, and two to three 
striatal samples from both sides were dissected and immediately frozen for later analyses. The remainder of the 
brain (including the striatum beginning just rostral to the level of the decussation of the anterior commissure) 
was submersion fixed in 4% paraformaldehyde.
Behavioral testing. Forelimb use during explorative activity was analyzed using the cylinder test. The test 
apparatus consisted of a clear Plexiglass cylinder of approximately 33 cm diameter and 50 cm height placed in a 
dimly lit room in front of a mirror in order to visualize limb use from all angles. Each session was videotaped 
for later analysis by an observer blind to the animal’s experimental group. The paw contralateral to the side of 
the AAV-A53T-α-synuclein injection was marked prior to the start of each test session to definitively determine 
laterality on videotapes. The test was performed in the late afternoon at the same approximate time for each test 
session. At each test session, the animal was gently placed in the cylinder and movements were videotaped for 
10 minutes. Forelimb use was assessed by scoring weight-bearing contacts on the cylinder wall with the ipsilateral, 
contralateral (relative to the AAV-A53T-α-synuclein-injected side), and both paws. Twenty observations of the 
paw placements on the cylinder wall were scored.
Limb placement on the wall was scored only if it occurred after the animal returned to a resting position and 
reared again to touch the cylinder wall. Percent ipsilateral (ipsi) and contralateral (contra) paw touches were 
calculated as [(ipsi + 1/2 both)/total # observations] * 100 and [(contra + 1/2 both) /total # observations] * 100, 
respectively. The cylinder test was performed prior to surgery (baseline) and at 3 and 6 weeks after surgery for the 
immediate start GM1 groups and at 3 and 8 weeks after surgery for the delayed start GM1 groups.
Measurement of striatal dopamine and metabolite levels. Striatal samples were sonicated cold 
in 0.4 M perchloric acid for 10 seconds and centrifuged at 13,000 rpm for 10 min at 4 °C. The supernatant was 
removed and was diluted 1:4 with Milli-Q ultrapure water (resistivity 18.2 MΩ·cm) containing internal standard 
(isoproterenol, 4 ng). The diluted samples were centrifuged again at 13,000 rpm for 5 min at 4 °C. Samples were 
kept on ice prior to loading into the refrigerated (4 °C) autosampler integrated with the HPLC system.
An ALEXYS UHPLC system (Antec Scientific) with electrochemical detection (Decade Elite electrochemical 
detector with a glassy carbon electrode) was used for the analyses. Separations were achieved using an Aquity 
UPLC column 1.0 × 100 mm BEH C18 1.7 um (Waters Corporation). The mobile phase (pH 3.0) consisted of 
100 mM phosphoric acid, 100 mM citric acid, 0.1 mM EDTA.Na2, 600 mg/L octanesulfonic acid sodium salt, 
and 8% acetonitrile. Pump flow rate was 50 µl/min. The analytes were detected at an oxidation potential of 
600 mV against a reference electrode at 0 mV. Data were acquired and processed using Clarity software (v7.4.1) 
(DataApex). Peak heights were compared against standard curves to determine the concentrations of DA and 
metabolites in each sample.
Immunohistochemistry and stereological cell counting. Fixed tissue blocks were immersed in 30% 
sucrose for cryoprotection and sectioned frozen on a sliding microtome (30 μm section thickness for striatal sec-
tions; 40 μm section thickness for SN sections). Sections through the rostro-caudal extent of the SN were collected 
and every sixth section from the SN was processed for tyrosine hydroxylase (TH) immunohistochemistry to be 
used for stereological cell counting. Three striatal sections from approximately the same anatomical level in each 
case were processed for α-synuclein immunohistochemistry.
For immunohistochemistry, sections were washed and permeabilized with PBS containing 0.2% Triton X-100. 
Endogenous peroxidase activity was quenched using 3% hydrogen peroxide in PBS containing 0.2% Triton X-100. 
Sections were then blocked in PBS/triton X-100 containing 10% normal goat serum and 2% BSA, followed by 
primary antibody incubation (TH (rabbit anti-TH, 1:2,000, Pel-Freez); α-synuclein (mouse anti-α-synuclein 
clone 211; 1:2000, Millipore) overnight at 4 °C. The following day, sections were washed in PBS and incubated in 
biotinylated secondary antibody (goat-anti-rabbit 1:4000 for TH; goat-anti-mouse 1:2000 for α-synuclein 1:2000, 
VECTOR Laboratories), followed by additional washes and incubation in avidin biotin complex (VECTASTAIN 
Elite ABC system, VECTOR Laboratories). The reaction product was visualized with 3,3′-diaminobenzidine 
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(DAB) (Immpact DAB, VECTOR Laboratories). Sections were then mounted, dehydrated, cleared and covers-
lipped. Sections stained for visualization of TH and to be used for stereological cell counting were counterstained 
with cresyl violet48 prior to coverslipping.
Stereological estimates of the numbers of TH and cresyl violet-stained neurons in the SNc on both sides of 
the brain were obtained using StereoInvestigator software (MBF Bioscience) and an Olympus BX-60 microscope 
equipped with a Ludl motorized stage. Slides were coded and analyzed blindly. The SNc was outlined under low 
magnification (4x) and a grid measuring 195 μm × 85 μm was randomly placed over the region. Cells were then 
counted at high power (100x) using a counting frame measuring 60 μm2. A cell was counted only if a nucleus was 
clearly identifiable and the cell was within the counting frame and did not contact the left or bottom boundary of 
the counting frame. This process was repeated for each section in the series for a given animal, and a total of 7–8 
sections/animal were analyzed. Nissl-stained cells were counted concurrently in the same sections using the same 
sampling parameters. Cell counts were considered acceptable with a Gundersen CE < 0.1.
Analysis of α-synuclein and α-synuclein-positive aggregates. Immunoblotting for α-synuclein 
expression was performed using the Wes western blot system (ProteinSimple). Tissue lysates were prepared 
in standard RIPA buffer supplemented with protease inhibitors and were resolved using the 12–230 KDa 
Wes separation module according to the manufacturer’s recommendations. α-synuclein levels were assayed 
using anti-α-synuclein antibody (Syn204) (Cat. No. 2647S, Cell Signaling) and normalized to β-actin levels 
(anti-beta-actin antibody, NB600-503, Novus Biologicals) (See Supplementary Material for addition immunob-
lotting method details).
Recent in vitro studies suggest that GM1 and α-synuclein interact in a way that protects monomeric 
α-synuclein from potentially pathogenic aggregation32. We investigated the extent to which GM1 treatment in 
vivo might affect the aggregation of α-synuclein by measuring the size of α-synuclein-positive aggregates in the 
striatum of AAV-A53T animals treated with saline or GM1. The sizes of α-synuclein-positive swelling/aggregates 
were measured in 3 fields (one medial, one central and one lateral) from 1 coronal section (at the same approx-
imate anatomical level in each animal). Photographs were captured using a 40x objective on a Nikon Eclipse Ni 
microscope and α-synuclein-positive structures with an area >5 µm2 were considered as aggregates and were 
measured using Nikon NIS Elements AR software. Data are presented as the distribution of aggregate sizes in the 
three striatal regions measured.
Exclusion of animals from analysis. A total of nine animals from all surgery groups were excluded from 
analysis due to no evidence of a successful lesion produced by AAV1/2-A53T α-synuclein injection. For technical 
reasons or for lack of sufficient tissue available for processing, two animals from the early start A-53T-α-synuclein/
saline group and four animals from the early start A-53T-α-synuclein/GM1 group were excluded from analysis 
of stereological cell counts. Also, for technical reasons or for lack of sufficient tissue available for processing, one 
animal from the delayed start A-53T-α-synuclein/saline group was excluded from the cylinder test analysis and 
from the analysis of DOPAC levels; two animals from the delayed start A-53T-α-synuclein/GM1 group were 
excluded from analysis of stereological cell counts and from analysis of DOPAC levels.
Statistical analyses. All statistics were performed using GraphPad Prism software (v7). Values are pre-
sented as means ± SEM. Comparisons between experimental groups were performed using Student’s t test or 
when comparisons involved more than two groups, one-way analysis of variance followed by post hoc compari-
sons using Bonferroni’s multiple comparison test. All analyses were two-sided. The nonparametric Kolmogorov 
Smirnov test was used to test whether samples of α-synuclein aggregate sizes from saline and GM1-treated ani-
mals came from the same distribution or not (i.e., H0: the two samples come from a common distribution; Ha: the 
two samples do not come from a common distribution). In all cases, statistical significance was set at P < 0.05. All 
data are available upon request.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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